Anlotinib Plus Osimertinib in Osimertinib‐Resistant Nonsquamous Nonsmall Cell Lung Cancer With Gradual Progression: A Retrospective Study

Anlotinib Plus Osimertinib in Osimertinib‐Resistant Nonsquamous Nonsmall Cell Lung Cancer With Gradual Progression: A Retrospective Study

ABSTRACT Background Previous studies have shown that anlotinib plus third‐generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) overcome acquired resistance to EGFR‐TKIs in patients with advanced EGFR‐mutant nonsmall cell lung cancer (NSCLC). This study aimed to retrospe...

Full description

Saved in:
Bibliographic Details
Main Authors: Yu Hua, Minghui Liu, Boshi Li, Hongbing Zhang, Zihe Zhang, Yanan Wang, Jinghao Liu, Xin Li, Yongwen Li, Sen Wei, Hongyu Liu, Jun Chen
Format: Article
Language:English
Published: Wiley 2025-05-01
Series:Thoracic Cancer
Subjects:
anlotinib
nonsquamous nonsmall cell lung cancer
osimertinib
resistance
Online Access:https://doi.org/10.1111/1759-7714.70071
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1111/1759-7714.70071

Similar Items